JNNP: cerebrospinal fluid β-synuclein as an early diagnostic marker for Alzheimer's disease

synactal nuclein (synuclein) is a protein found in the pre-synactal endings and neuron nucleus in α, β and γ proteins.
, α-synactal nucleoproteins (α-synuclein) are associated with diseases such as Parkinson's disease.
-synuclein α in nerve cells in the brain play a key role in Parkinson's disease and other neurodegenerative diseases.
these protein lumps can spread between nerve cells, leading to the disease's exacerbation.
Previous proteomics studies have found significant changes in proteins in plasma, serum, and cerebrospinal fluid in Alzheimer's (AD) patients, but none of these studies have obtained accurate, specific, and repeatable AD diagnostic markers.
, determining AD diagnostic biomarkers remains a major challenge.
, synapse loss played an important role in AD disease.
, synapse loss has not been introduced into AD clinical routine testing as a neurochemical marker.
through pre-mass spectrometry, β-synuclein has been established as a potential AD candidate marker.
this, a team of researchers from Ulm University School of Medicine in Germany developed a new β-synuclein ELISA test kit and assessed its potential as an AD diagnostic and predictive marker.
the results were published in the journal Journal of Neurology and Psychic.
researchers analyzed 393 patients from four clinical centers.
diagnostic groups include: AD group (n=151), behavioral variability with temporal dementia (bvFTD, n=18), Parkinson's syndrome (n=46), Kerja's disease (CJD, n=23), amyotrophic lateral sclerosis (ALS, n=29), disease control group (n=66) and 60 non-neurodegenerative control patients.
the main measurements were the comparison of AD core biomarkers (total tau, phosphate tau and amyloid proteins and β peptides 1-42) with β-synuclein.
addition, the study quantitatively tested the β-synuclein level in the brain plasma and assessed the coexistence of β-synuclein with the bubble glutamate transporter 1 (VGLUT1).
results showed a strong correlation between the β-synuclein level of the newly developed ELISA kit quantitative test and the mass spectrometry protein detection (r=0.92 (95% CI:0.89-0.94), p<0.0001).
levels of cerebrospinal fluid β-synuclein increased in AD-mild cognitive impairment (p-lt;0.0001), AD dementia (p-lt;0.0001) and CJD (p-lt;0.0001), but not in bvFTD, Parkinson's syndrome, or ALS.
addition, β-synuclein was positioned in VGLUT1-positive glutamate synapses, which significantly reduced expression in brain tissue in AD patients .
researchers believe the study proves that β-synuclein is positioned in glutamate synapses and that the ELISA kit is highly sensitive and stable for measuring β-synuclein.
addition, the findings confirm previous studies that have given mass spectrometry, i.e. increased levels of β-synuclein in CSF in AD and CJD patients, supporting its potential use as a synapse degeneration marker.
: Halbgebauer S, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 Dec 30:jnnp-2020-324306. doi: 10.1136/jnnp-2020-324306. MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here